Your browser doesn't support javascript.
loading
Patient-derived micro-organospheres enable clinical precision oncology.
Ding, Shengli; Hsu, Carolyn; Wang, Zhaohui; Natesh, Naveen R; Millen, Rosemary; Negrete, Marcos; Giroux, Nicholas; Rivera, Grecia O; Dohlman, Anders; Bose, Shree; Rotstein, Tomer; Spiller, Kassandra; Yeung, Athena; Sun, Zhiguo; Jiang, Chongming; Xi, Rui; Wilkin, Benjamin; Randon, Peggy M; Williamson, Ian; Nelson, Daniel A; Delubac, Daniel; Oh, Sehwa; Rupprecht, Gabrielle; Isaacs, James; Jia, Jingquan; Chen, Chao; Shen, John Paul; Kopetz, Scott; McCall, Shannon; Smith, Amber; Gjorevski, Nikolche; Walz, Antje-Christine; Antonia, Scott; Marrer-Berger, Estelle; Clevers, Hans; Hsu, David; Shen, Xiling.
Afiliação
  • Ding S; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA; Xilis, Inc., Durham, NC 27713, USA.
  • Hsu C; College of Arts and Sciences, University of Chapel Hill, Chapel Hill, NC 27599, USA.
  • Wang Z; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA; Xilis, Inc., Durham, NC 27713, USA.
  • Natesh NR; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Millen R; Oncode, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center (UMC) Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
  • Negrete M; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Giroux N; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Rivera GO; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Dohlman A; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Bose S; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Rotstein T; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Spiller K; Xilis, Inc., Durham, NC 27713, USA.
  • Yeung A; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Sun Z; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Jiang C; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
  • Xi R; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Wilkin B; Xilis, Inc., Durham, NC 27713, USA.
  • Randon PM; National Institute of Environmental Health Sciences (NIEHS), Durham, NC 27709, USA.
  • Williamson I; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Nelson DA; Xilis, Inc., Durham, NC 27713, USA.
  • Delubac D; Xilis, Inc., Durham, NC 27713, USA.
  • Oh S; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
  • Rupprecht G; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
  • Isaacs J; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
  • Jia J; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
  • Chen C; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
  • Shen JP; Department of Gastrointestinal Medical Oncology, MD Anderson, Houston, TX 77030, USA.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, MD Anderson, Houston, TX 77030, USA.
  • McCall S; Department of Pathology, Duke University, Durham, NC 27708, USA.
  • Smith A; Xilis, Inc., Durham, NC 27713, USA.
  • Gjorevski N; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland.
  • Walz AC; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland.
  • Antonia S; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
  • Marrer-Berger E; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland.
  • Clevers H; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands; Oncode, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center (UMC) Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Roche Pharmaceutical Resear
  • Hsu D; Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA. Electronic address: shiaowen.hsu@duke.edu.
  • Shen X; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA. Electronic address: xiling.shen@terasaki.org.
Cell Stem Cell ; 29(6): 905-917.e6, 2022 06 02.
Article em En | MEDLINE | ID: mdl-35508177
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Colo / Medicina de Precisão Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Colo / Medicina de Precisão Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article